Clinical Trial Update: HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial using HIM typing to guide first-line treatment for advanced triple-negative breast cancer; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Advanced Triple Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING